Risuteganib improves visual acuity in patients with dry AMD in phase 2a study
Click Here to Manage Email Alerts
NEW ORLEANS — Patients with intermediate dry age-related macular degeneration experienced meaningful improvement in visual acuity after treatment with risuteganib, according to a study.
“We’re treating patients 5 to 7 years before geographic atrophy,” Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics, said in a presentation at the Eyecelerator meeting. “We have the potential to not only reverse vision loss, but also get functional vision back.”
Karageozian discussed data from a phase 2a study that compared risuteganib (Allegro) with sham in 39 patients with dry AMD. The primary endpoint was the percentage of patients with at least an eight-letter gain in best corrected visual acuity at week 28 compared with sham at week 12.
At week 28, 48% of patients in the risuteganib group met the primary endpoint compared with 7.1% of patients at week 12 in the sham group (P = .013).
Additionally, 32% of patients in the risuteganib group experienced at least 10 letters of improvement and 20% experienced at least 15 letters of improvement compared with 7.1% and 0% in the sham group, respectively.
Investigator analysis also found that by using baseline OCT, it is possible to identify which patients might be responders to therapy with risuteganib.
“How much damage is the point of no return,” Karageozian said. “The better the outer retinal thickness is, the more likely you are to get a visual acuity improvement.”
Collapse
Karageozian V. Targeting vision improvement in intermediate dry AMD with risuteganib. Presented at: Eyecelerator; Nov. 11, 2021; New Orleans.
Read more about
Click Here to Manage Email Alerts